I know it's just a couple minutes left, so I will do a quick through my slides. So my topic today is the growth of senitinellins and albaxes in research workstations in endometrial cancer. So first, I have no conflicts of interest to disclose. So we will talk about four points in today's with endometrial cancer, senitinellin phenol, and why the senitinellin phenol activates lymphadenitinase in the early stage of endometrial cancer. And the last point is the dyes. So first of all, the endometrial cancer is the global cancer that has about the worldwide endometrial cancer. Endometrial cancer is the sixth most common malignancy in women. There was more than 417,000 new cases of the endometrial cancer in the 2020s. And also in Vietnam, the endometrial cancer is also the sixth most common cancer in women, and there were 5,300 new cases of endometrial cancer in the 2020s. Because endometrial cancer typically is diagnosed in the early stage, so the women with this diagnosis usually do very well, and the five-year overall survival of the early stage endometrial cancer is over 90%, and in the early stage disease, the standard treatment is so great. The complex cervical stagings for the endometrial cancer include the total hysterectomy, centripetal operations, and lymph node attachments. Removal of the lymph nodes alone has not been thought to be the therapeutic in and of itself, but it is important after determining both the prognosis and post-operating or adjuvant treatment. So the principles of the senitineal lymph node mapping, the senitineal lymph node mapping is an approach to the lymph node assessment that's allowed to remove fewer lymph nodes. If the senitineal lymph node mapping, you ingest a tracer, either the titanium or the dye, into the organs in order to determine the first lymph node running in that organ. The first lymph node that shows the tracer will be the first lymph node that the cancer will typically go to. This is a pioneer in the melanoma and breast cancer, but it is now in use in the other solid tumor types. In the gynecological cancer, it's used in the vulva, cervical, and endometrial cancer. Besides that, the toxics of lymphadenatamines are the injure of mobility, such as vascular nerve injury, and increase the blood stress. So, we got the GOG 33, the study's prognosis is evaluated 621 patients in the clinical staging endometrial cancer. All the patients underwent the standard staging procedures with TSA, ESVS, and collect pelvic washing, and selecting the pelvis and parietal lymph node assessment. And you can see the results in the table here. With the patient with a low-risk disease, in fact, in the grade one tumor with the endometrial involved, not on this, and no in child disease, has no pelvis and parietal lymph node metastasis. And those of the moderate-risk disease, the device is under 15% myometrial-invasive and no intraperitoneum disease has 3%, from 3% to 6% incidence of the pelvis lymph nodes and 2% incidence of the parietal lymph node involvement. The high-risk disease device is to classify myometrial-invasive and intraperitoneum disease. Those with myometrial-invasive has 18% and 15% incidence of the pelvis and parietal lymph node metastasis. And the patient with the intraperitoneum disease has only under 15% myo-involved, has a risk of 33% risk of the pelvis lymph node metastasis and 8% risk of a positive parietal lymph node. The patient is both of the high-risk, caries have a high risk, with a 16% pelvic lymph node metastasis and 30% parietal lymph node involvement. So the question is, whether the secondary lymph nodes are attenuated to the lymphadenectomy or not. In the two large protected trials, the FIRE trial and SENTI-ENDO trial, it shows the secondary lymph node detections improves the detections of the lymph node metastasis when compared with a full lymph node dissection. It also decreased the risk of complications, increased the risk of lymphatic mass, morosity, nodal status, allowed to the tolerance and avoidance of the adjuvant therapy. So we have a feature of the FIRE trial comparing the secondary lymph node metastasis to the lymphadenectomy endometrial cancer. And in this trial with 314 patients, we got a pelvis lymphadenectomy with 100% and the successful markings of the secondary lymph node is just 18-16%. And bilateral mapping is 15-2%. And the isolated parietal lymph node metastasis is just under 1%. So the outcome of the FIRE trial with the SENTITIS is a 1970% and the negative predict value is 99%. So the isolated parietal lymph node with negative SENTITIS lymph node in just 3 patients is under 1%. And also the same result with the SENTITIS-NILS-ENDO trials with the overall detection is 18-9%. With the parietal lymph node is 5%. And the SENTITIS is with 18-40%. The negative predict value is 97%. And the disease of pre-survival is 50 months with 18-40%. And we also have another trial from the Balint doctors with the SENTITIS-NILS lymph node. We got a detection rate is 81%. And with SENTITIS is 89%. And 89%, the post-negative rate is just 1.9%. The negative predict is 99%. So it's a beautiful result from the three trials for improving the SENTITIS-NILS lymph node allocated with TUN lymphadenation midisection. So the outcome from the trials with 3-year DFS is 94% and 93% in the MAZEO trial and MSK trial. So the summary we have the SENTITIS-NILS lymph node in the endometrial cancer is about to be safe and effective of the lymph node assessment in the endometrial cancer. It also decrease the risk of complications, includes a 3% decreased rate of lymphadenema. And the decrease is very significant. The rate of lymphadenema is post-lymph node dissection approximately 18%. And in the SENTITIS-NILS lymph node dissection, it is not only 1%. The SENTITIS-NILS lymph node masking in the endometrial cancer is typically performed with a blue dye or endocaine spray or ICD. But the use of the ICD requires the ability to use a near-infrared machine. So this is applicable to the testable equipment that can be used in open laboratory or robotic case. So the blue dye is the most common dye used in identifying the SENTITIS-NILS lymph node back to the 2010s ago. You can see a lot of trials from back to the 2010s where you use the blue dyes. But now the events of the increased acceptance here to infrared of the fluorescence imaging for the laparoscopic, robotic, and open-platform ICD has become increasingly popular. It has been sold that have equivalent and better detected traits in the SENTITIS-NILS lymph node and uterine cancer. The last phase is about talk about the comparison with the ICDs and the blue dyes. You can see the ICDs is more detected traits of the SENTITIS-NILS lymph nodes and the blue dyes. And so summarize is the SENTITIS-NILS lymph node is so safe and effective of the lymph node detection in the endometrial cancer. And the SENTITIS-NILS lymph node improves the detection of the lymph node metastasis compared with the full lymph node detection. And the ICDs is preferred than the blue dyes and SENTITIS-NILS lymph node in the endometrial cancer. Thank you.

endometrial cancer

lymph node assessment

senitineal lymph node mapping

infrared fluorescence imaging

safety